Rocephin and Osteolysis - a phase IV clinical study of FDA data

Summary:

Osteolysis is reported as a side effect among people who take Rocephin (ceftriaxone sodium), especially for people who are female, 50-59 old, also take Zometa, and have Osteoporosis.

The phase IV clinical study analyzes which people have Osteolysis when taking Rocephin. It is created by eHealthMe based on reports of 15,458 people who have side effects when taking Rocephin from the FDA, and is updated regularly.

What is Rocephin?

Rocephin has active ingredients of ceftriaxone sodium. It is often used in infection. eHealthMe is studying from 15,665 Rocephin users. Check the latest studies of Rocephin.

What is Osteolysis?

Osteolysis (dissolution of bone) is found to be associated with 688 drugs and 407 conditions by eHealthMe. Check the latest studies of Osteolysis.

On Jul, 06, 2026

15,458 people reported to have side effects when taking Rocephin.
Among them, 74 people (0.48%) have Osteolysis.

Among these 74 people:

What is the gender of people who have Osteolysis when taking Rocephin? *

female: 81.94 %
male: 18.06 %

What is the age of people who have Osteolysis when taking Rocephin? *

What are other drugs people take besides Rocephin? *

What are other side effects people have besides Osteolysis? *

Pain: 72 people, 97.30%
Pleural Effusion (water on the lungs): 56 people, 75.68%
Osteonecrosis Of Jaw (death of bone of jaw): 56 people, 75.68%
Diarrhea: 55 people, 74.32%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 55 people, 74.32%
Spinal Osteoarthritis (joint cartilage loss in spine): 52 people, 70.27%
Osteopenia (a condition where bone mineral density is lower than normal): 50 people, 67.57%
Sepsis (a severe blood infection that can lead to organ failure and death): 50 people, 67.57%
Oedema Peripheral (superficial swelling): 50 people, 67.57%
Osteoporosis (bones weak and more likely to break): 50 people, 67.57%

What are the existing conditions these people have? *

Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 33 people, 44.59%
Osteoporosis (bones weak and more likely to break): 33 people, 44.59%
Metastases To Bone (cancer spreads to bone): 12 people, 16.22%
Thrombocytopenia (decrease of platelets in blood): 11 people, 14.86%
Multiple Myeloma (cancer of the plasma cells): 9 people, 12.16%
Stress And Anxiety: 7 people, 9.46%
Bone Disorder: 7 people, 9.46%
Breast Cancer: 5 people, 6.76%
Fatigue (feeling of tiredness): 5 people, 6.76%
Urticaria (rash of round, red welts on the skin that itch intensely): 2 people, 2.70%

* Approximation only. Some reports may have incomplete information.

Do you take Rocephin and have Osteolysis?

- Check whether Osteolysis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rocephin:

Rocephin (15,665 reports)

Osteolysis treatments and more:

Osteolysis (4,092 reports)

Browse all side effects of Rocephin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Osteolysis:

Osteolysis (688 drugs)

Browse all the conditions that are associated with Osteolysis:

Osteolysis (407 conditions)

Related publications that referenced our studies

Agrawal SR, Rajput A, Jain AP, "Leukocytoclastic vasculitis and acute allergic interstitial nephritis following ceftriaxone exposure", Journal of pharmacology & pharmacotherapeutics, 2014 Jan .
Agrawal SR, Rajput A, Jain AP, "Leukocytoclastic vasculitis and acute allergic interstitial nephritis following ceftriaxone exposure", Journal of pharmacology & pharmacotherapeutics, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on ceftriaxone sodium (the active ingredients of Rocephin) and Rocephin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.